EUVIMEDEUVIMED entdecken
Crossref

Preclinical Evaluation of 99m Tc-MAG 3 -5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with 99m Tc-MAG 3 -5-F(ab′) 2

Dai Shi iD, Wenhui Fu, Hui Tan, Qingyu Lin, Hongcheng Shi, Dengfeng Cheng iD

Molecular Pharmaceutics · 2024

DOI: 10.1021/acs.molpharmaceut.3c00870 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2024. Verfasst von Dai Shi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China. Hauptthemen laut MEDLINE: Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: Zhongshan Hospital, National Natural Science Foundation of China, Program of Shanghai Academic Research Leader.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triggering receptor expressed on myeloid cells-2 (TREM2), which is expressed on the surface of tumor-associated macrophages (TAMs), has been found to play a major role in the diagnosis and treatment of tumors. TREM2 expression is significantly upregulated in tumor tissues, and therefore, targeting TREM2 for tumor imaging may be of value. Previously, we performed TREM2 targeting imaging by using 68Ga-NOTA-COG1410 or a 124I-labeled monoclonal antibody (mAb) and F(ab')2 in mouse models of colon and gastric tumors. However, some of the shortcomings of these probes (i.e., the high uptake of 68Ga-NOTA-COG1410 in the liver, the difficulty of obtaining iodine-124, and the long half-life of iodine-124) have hindered their clinical use. Herein, we sought to synthesize novel molecular probes targeting TREM2 that are more conducive to clinical translation, eliminating the interference of isotope availability and in vivo probe biodistribution issues. Therefore, we established A549 cell lines with negative human TREM2 (hTREM2) expression (GFP tag; hTREM2- A549) or upregulated hTREM2 expression (GFP tag; hTREM2+ A549) using lentiviral transfection and confirmed these with Western blotting and immunocytochemistry. We then prepared a mouse anti-human TREM2 (5-mAb) by immunizing with the hTREM2 antigen. The antibody fragments 5-F(ab')2 and 5-Fab were prepared from 5-mAb, and 99mTc-MAG3-5-F(ab')2 and 99mTc-MAG3-5-Fab were then synthesized with excellent stability and specificity. 99mTc-MAG3-5-F(ab')2 had a slightly higher in vitro affinity than 99mTc-MAG3-5-Fab (Kd = 3.32 ± 0.05 nmol versus 4.62 ± 0.85 nmol). 99mTc-MAG3-5-F(ab')2 and 99mTc-MAG3-5-Fab both showed excellent specificity: after adding a 100-fold precursor, the two probes binding to the cells were almost blocked. In vivo pharmacokinetics showed that the distribution and elimination half-lives of 99mTc-MAG3-5-Fab (T1/2α = 1.25 ± 0.30 min and T1/2β = 21.98 ± 2.80 min, respectively) were significantly reduced compared to those of 99mTc-MAG3-5-F(ab')2 (T1/2α = 2.64 ± 0.37 min and T1/2β = 86.55 ± 26.86 min, respectively). In micro single-photon emission computed tomography/computed tomography (micro-SPECT/CT) imaging, the tumor was clearly displayed at 1 h after 99mTc-MAG3-5-Fab injection, while the blood background was extremely low at 3 h, and the probe was mainly excreted through the kidneys and biliary tract. 99mTc-MAG3-5-F(ab')2 uptake was also detected at the tumor site, although the blood background was consistently high. The biodistribution results were consistent with the micro-SPECT/CT imaging results. 99mTc-MAG3-5-Fab could clearly display hTREM2+ A549 tumors in a short time (1 h) with low uptake in nontumor organs and tissues and thus has clinical application prospects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lung NeoplasmsHumansAnimalsMiceTissue DistributionGallium RadioisotopesImmunoglobulin Fab FragmentsTechnetium Tc 99m MertiatideAntibodies, MonoclonalMembrane GlycoproteinsReceptors, ImmunologicIodine Radioisotopes

Stichwörter der Autor:innen

5-mAb99mTcF(ab′)2FabTREM2micro-SPECT/CT

Substanzen

Gallium RadioisotopesImmunoglobulin Fab FragmentsTechnetium Tc 99m MertiatideAntibodies, MonoclonalMembrane GlycoproteinsReceptors, ImmunologicIodine-124Iodine RadioisotopesTREM2 protein, human

Autor:innen und Institutionen

  • Department of Nuclear Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
  • Shanghai Institute of Medical Imaging, Shanghai 200032, China.
  • Institute of Nuclear Medicine, Fudan University, Shanghai 200032, China.
  • Cancer Prevention and Treatment Center, Zhongshan Hospital, Fudan University, Shanghai 200032, China.

ORCID-Profile: Dai Shi, Dengfeng Cheng

Förderung

  • Zhongshan Hospital
  • National Natural Science Foundation of China
  • Program of Shanghai Academic Research Leader

Zitieren

APA

Shi, D., Fu, W., Tan, H., Lin, Q., Shi, H., & Cheng, D. (2024). Preclinical Evaluation of 99m Tc-MAG 3 -5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with 99m Tc-MAG 3 -5-F(ab′) 2. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00870

Vancouver

Shi D, Fu W, Tan H, Lin Q, Shi H, Cheng D. Preclinical Evaluation of 99m Tc-MAG 3 -5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with 99m Tc-MAG 3 -5-F(ab′) 2. Molecular Pharmaceutics. 2024. doi:10.1021/acs.molpharmaceut.3c00870

BibTeX
@article{Shi2024,
  author = {Shi, Dai and Fu, Wenhui and Tan, Hui and Lin, Qingyu and Shi, Hongcheng and Cheng, Dengfeng},
  title = {Preclinical Evaluation of 99m Tc-MAG 3 -5-Fab Targeting TREM2 in Lung Cancer Mouse Models: A Comparison with 99m Tc-MAG 3 -5-F(ab′) 2},
  journal = {Molecular Pharmaceutics},
  year = {2024},
  doi = {10.1021/acs.molpharmaceut.3c00870}
}
Kostenlos starten →